United Health Products, Inc. (OTCQB: UEEC.PK) wholly owned subsidiary, Epic Wound Care, Inc., which develops and markets products and technologies in the healthcare sector, today announced that its hemostatic gauze, which is registered and branded in the USA under the trademark HemoStyp™, has been approved and featured in the Clinicians Report®. The report is a published scientific testimonial that features products which have met the criteria and approval of the dental community. The Clinicians Report® is a 35-year-old industry publication serving as an informative tool to the dental industry with distribution to over 10,000 dental care providers. It features new products with published test results that have been tested and approved by dentists and the dental community. In this case, 70% of evaluators stated that they would incorporate HemoStyp™ into their practice. Additionally, 83% rated the product excellent or good and worthy of trial by colleagues. Dr. Philip Forman, CEO of United Health Products Inc., acknowledged the importance of being featured in the Clinicians Report®, stating that the testimonies and the testing results validate the HemoStyp™ gauze and the use of the product in the dental industry. The Report also is a great method of introducing approved products that have been tested and used by dentists and dental technicians with their comments. Dr. Forman stated as a result of the report the company has received an initial order from one of the dental industry’s largest dental products distributors and has numerous requests for product. The Clinicians Report® Sept. edition can been viewed at the following link for a nominal fee – www.cliniciansreport.org/products/dental-reports.
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures and markets products and technologies in the healthcare sector. UEEC's operating subsidiary Epic Wound Care, Inc. produces hemostatic gauze, derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying emerging healthcare products and technologies for strategic partnership or acquisition.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Dr. Philip Forman, 646-961-4459